OTDOncology Treatment Discovery3083-49962981-8079Bio-Byword Scientific Publishing Pty. Ltd.10.26689/otd.v2i4.7956ArticleComprehensive Bioinformatics Evaluation of CTNNB1 as a Diagnostic, Therapeutic and Prognostic Biomarker in Liver Hepatocellular Carcinomahttps://artdesignp.com/journal/OTD/2/4/10.26689/otd.v2i4.7956RazaSyed Hussain,AkramMuhammad2024242024-12-31Liver Hepatocellular Cancer (LIHC) is a fatal disease, that keeps rigorous to therapeutic approach. This study explores the expression and promoter methylation of CTNNB1 and survival analysis, to extricate its role in LIHC progression, prognosis, and therapeutic approaches. Employing UALCAN, the study examined upregulation in CTNNB1 expression in LIHC as compared to normal samples explained its role in LIHC progression. Further analysis, stratified by patient’s age, gender, race, and pathological stages, revealed upregulation across all variables. Analysis of promoter methylation level of CTNNB1 in LIHC revealed hypomethylation, acknowledging upregulation of expression. Moreover, survival analysis of CTNNB1 using a KM plotter demonstrated its prognostic significance, as CTNNB1 overexpression results in the worst overall survival (OS) and vice versa. Validation via GEPIA2 affirmed elevated expression level of CTNNB1 in LIHC, further establishing its correlation with unfavorable survival outcomes. Furthermore, pathway enrichment analysis utilizing the STRING and DAVID tool identified association with genes implicated in essential signaling processes such as the Wnt signaling pathway revealing its role in LIHC progression. Subsequently, Genetic mutation analysis performed using cBioPortal demonstrated a 10% mutation of CTNNB1 in LIHC, indicating that alteration in the gene has a critical role in the development of LIHC. In conclusion, this comprehensive analysis highlights the significance of CTNNB1 upregulation in LIHC progression and its capability as a prognostic biomarker, offering valuable insight for developing targeted therapeutic strategies.

Sung H, Ferlay J, Siegel RL, et al., 2021, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3): 209–249.

Tao S, Ye X, Pan L, et al., 2021, Construction and Clinical Translation of Causal Pan-Cancer Gene Score Across Cancer Types. Frontiers in Genetics, 12: 784775.

Andre F, Mardis E, Salm M, et al., 2014, Prioritizing Targets for Precision Cancer Medicine. Annals of Oncology, 25(12): 2295–2303.

Sial N, Saeed S, Ahmad M, et al., 2021, Multi-Omics Analysis Identified TMED2 as a Shared Potential Biomarker in Six Subtypes of Human Cancer. International Journal of General Medicine, 2021: 7025–7042.

Anwanwan D, Singh SK, Singh S, et al., 2020, Challenges in Liver Cancer and Possible Treatment Approaches. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1873(1): 188314.

Bray F, Ferlay J, Soerjomataram I, et al., 2018, Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68(6): 394–424.

Balogh J, Victor III D, Asham EH, et al., 2016, Hepatocellular Carcinoma: A Review. Journal of Hepatocellular Carcinoma, 2016: 41–53.

Llovet JM, Castet F, Heikenwalder M, et al., 2022, Immunotherapies for Hepatocellular Carcinoma. Nature Reviews Clinical Oncology, 19(3): 151–172.

Park JW, Chen M, Colombo M, et al., 2015, Global Patterns of Hepatocellular Carcinoma Management from Diagnosis to Death: The BRIDGE Study. Liver International, 35(9): 2155–2166.

Heimbach JK, Kulik LM, Finn RS, et al., 2018, AASLD Guidelines for the Treatment of Hepatocellular Carcinoma. Hepatology, 67(1): 358–380.

Liu CY, Chen KF, Chen PJ, 2015, Treatment of Liver Cancer. Cold Spring Harbor Perspectives in Medicine, 5(9): a021535.

Finn RS, Qin S, Ikeda M, et al., 2020, Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma. New England Journal of Medicine, 382(20): 1894–1905.

Dhir M, Melin AA, Douaiher J, et al., 2016, A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Annals of Surgery, 263(6): 1112–1125.

Poon D, Anderson BO, Chen LT, et al., 2009, Management of Hepatocellular Carcinoma in Asia: Consensus Statement from the Asian Oncology Summit 2009. The Lancet Oncology, 10(11): 1111–1118.

Ouyang X, Fan Q, Ling G, et al., 2020, Identification of Diagnostic Biomarkers and Subtypes of Liver Hepatocellular Carcinoma by Multi-Omics Data Analysis. Genes (Basel), 11(9): 1051.

Kaur H, Bhalla S, Raghava GPS, 2019, Classification of Early and Late Stage Liver Hepatocellular Carcinoma Patients from Their Genomics and Epigenomics Profiles. PLoS One, 14(9): e0221476.

Huang A, Yang XR, Chung WY, et al., 2020, Targeted Therapy for Hepatocellular Carcinoma. Signal Transduction and Targeted Therapy, 5(1): 146.

Zhang W, Yang C, Hu Y, et al., 2023, Comprehensive Analysis of the Correlation of the Pan-Cancer Gene HAUS5 with Prognosis and Immune Infiltration in Liver Cancer. Scientific Reports, 13(1): 2409.

Khalaf AM, Fuentes D, Morshid AI, et al., 2018, Role of Wnt/β-Catenin Signaling in Hepatocellular Carcinoma, Pathogenesis, and Clinical Significance. Journal of Hepatocellular Carcinoma, 2018: 61–73.

Li QM, Zhang FQ, Li YF, et al., 2017, Influence of Polymorphisms in the Wnt/β-Catenin Pathway Genes on Hepatocellular Carcinoma Risk in a Chinese Han Population. Medicine, 96(12): e6127.

Pez F, Lopez A, Kim M, et al., 2013, Wnt Signaling and Hepatocarcinogenesis: Molecular Targets for the Development of Innovative Anticancer Drugs. Journal of Hepatology, 59(5): 1107–1117.

Chen L, Zhou Q, Liu J, et al., 2021, CTNNB1 Alteration is a Potential Biomarker for Immunotherapy Prognosis in Patients with Hepatocellular Carcinoma. Frontiers in Immunology, 12: 759565.

Xu C, Xu Z, Zhang Y, et al., 2022, β-Catenin Signaling in Hepatocellular Carcinoma. The Journal of Clinical Investigation, 132(4): e154515.

Chen J, Liu J, Jin R, et al., 2014, Cytoplasmic and/or Nuclear Expression of β-Catenin Correlate with Poor Prognosis and Unfavorable Clinicopathological Factors in Hepatocellular Carcinoma: A Meta-Analysis. PLoS One, 9(11): e111885.

Kim M, Lee HC, Tsedensodnom O, et al., 2008, Functional Interaction Between Wnt3 and Frizzled-7 Leads to Activation of the Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma Cells. Journal of Hepatology, 48(5): 780–791.

Cui J, Zhou X, Liu Y, et al., 2003, Wnt Signaling in Hepatocellular Carcinoma: Analysis of Mutation and Expression of Beta‐Catenin, T‐Cell Factor‐4 and Glycogen Synthase Kinase 3‐Beta Genes. Journal of Gastroenterology and Hepatology, 18(3): 280–287.

MacDonald BT, Tamai K, He X, 2009, Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases. Developmental Cell, 17(1): 9–26.

Javanmard D, Najafi M, Babaei MR, et al., 2020, Investigation of CTNNB1 Gene Mutations and Expression in Hepatocellular Carcinoma and Cirrhosis in Association with Hepatitis B Virus Infection. Infectious Agents and Cancer, 15: 37.

Tornesello ML, Buonaguro L, Tatangelo F, et al., 2013, Mutations in TP53, CTNNB1 and PIK3CA Genes in Hepatocellular Carcinoma Associated with Hepatitis B and Hepatitis C Virus Infections. Genomics, 102(2): 74–83.

Saitta C, Lanza M, Bertuccio A, et al., 2015, Evaluation of CTNNB1 and TP53 Variability in Patients with Hepatocellular Carcinoma and Occult Hepatitis B Virus Infection. Cancer Genetics, 208(10): 513–516.

Chen SP, Wu CC, Huang SY, et al., 2012, β-Catenin and K-ras Mutations and RASSF1A Promoter Methylation in Taiwanese Colorectal Cancer Patients. Genetic Testing and Molecular Biomarkers, 16(11): 1277–1281.

Nusse R, Clevers H, 2017, Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell, 169(6): 985–999.

Chandrashekar DS, Bashel B, Balasubramanya SAH, et al., 2017, UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia, 19(8): 649–658.

Győrffy B, Surowiak P, Budczies J, et al., 2013, Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer. PLoS One, 8(12): e82241.

Tang Z, Kang B, Li C, et al., 2019, GEPIA2: An Enhanced Web Server for Large-Scale Expression Profiling and Interactive Analysis. Nucleic Acids Research, 47(W1): W556–W560.

Mering C, Huynen M, Jaeggi D, et al., 2003, STRING: A Database of Predicted Functional Associations Between Proteins. Nucleic Acids Research, 31(1): 258–261.

Shannon P, Markiel A, Ozier O, et al., 2003, Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Research, 13(11): 2498–2504.

Da M, Zhuang J, Zhou Y, et al., 2021, Role of Long Noncoding RNA Taurine‐Upregulated Gene 1 in Cancers. Molecular Medicine, 27(1): 51.

Asakawa M, Itoh M, Suganami T, et al., 2019, Upregulation of Cancer-Associated Gene Expression in Activated Fibroblasts in a Mouse Model of Non-Alcoholic Steatohepatitis. Scientific Reports, 9(1): 19601.

Anastasiadi D, Esteve-Codina A, Piferrer F, 2018, Consistent Inverse Correlation Between DNA Methylation of the First Intron and Gene Expression Across Tissues and Species. Epigenetics & Chromatin, 11(1): 37.

Razin A, Cedar H, 1991, DNA Methylation and Gene Expression. Microbiological Reviews, 55(3): 451–458.

Polverini PJ, 2002, Angiogenesis in Health and Disease: Insights into Basic Mechanisms and Therapeutic Opportunities. Journal of Dental Education, 66(8): 962–975.

Olivier M, Hollstein M, Hainaut P, 2010, TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. Cold Spring Harbor Perspectives in Biology, 2(1): a001008.

Ledinek Ž, Sobočan M, Knez J, 2022, The Role of CTNNB1 in Endometrial Cancer. Disease Markers, 2022(1): 1442441.

Luczak MW, Jagodziński PP, 2006, The Role of DNA Methylation in Cancer Development. Folia Histochemica et Cytobiologica, 44(3): 143–154.